# A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

> **NCT00887341** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 76 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** tocilizumab [RoActemra/Actemra]
- **DRUG:** tocilizumab [RoActemra/Actemra]

## Key facts

- **NCT ID:** NCT00887341
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2014-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00887341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00887341, "A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00887341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*